Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
Copyright policy )Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAAs, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAAs or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAAs, providing assistance for a fruitful use of HCV resistance testing in clinical practice.
- University of Milan Italy
- University of Rome Tor Vergata Italy
- St. Paul's Hospital Canada
Genotype, Fold-change, Hepacivirus, Viral Nonstructural Proteins, Direct acting antiviral agents; Fold-change; HCV genotypic resistance testing; HCV sequencing; Treatment failure, Antiviral Agents, HCV genotypic resistance testing, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, DEAD-box RNA Helicases, Drug Resistance, Viral, Animals, Humans, Molecular Targeted Therapy, Treatment Failure, Direct acting antiviral agent, 360, Viral Proteases, Serine Endopeptidases, Hepatitis C, Chronic, Nucleoside-Triphosphatase, RNA-Dependent RNA Polymerase, Treatment failure, Drug Design, Mutation, HCV sequencing
Genotype, Fold-change, Hepacivirus, Viral Nonstructural Proteins, Direct acting antiviral agents; Fold-change; HCV genotypic resistance testing; HCV sequencing; Treatment failure, Antiviral Agents, HCV genotypic resistance testing, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, DEAD-box RNA Helicases, Drug Resistance, Viral, Animals, Humans, Molecular Targeted Therapy, Treatment Failure, Direct acting antiviral agent, 360, Viral Proteases, Serine Endopeptidases, Hepatitis C, Chronic, Nucleoside-Triphosphatase, RNA-Dependent RNA Polymerase, Treatment failure, Drug Design, Mutation, HCV sequencing
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).178 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
Citations provided by BIP!Popularity provided by BIP!